Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MBIO
stocks logo

MBIO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Valuation Metrics

The current forward P/E ratio for Mustang Bio Inc (MBIO.O) is -0.08, compared to its 5-year average forward P/E of -2.00. For a more detailed relative valuation and DCF analysis to assess Mustang Bio Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.00
Current PE
-0.08
Overvalued PE
0.76
Undervalued PE
-4.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.31
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.65
Undervalued EV/EBITDA
-1.28

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

MBIO News & Events

Events Timeline

(ET)
2025-07-07
08:32:00
Mustang Bio granted orphan drug designation by FDA for MB-101
select
2025-07-01 (ET)
2025-07-01
12:21:16
Mustang Bio treatment of malignant glioma granted orphan designation
select
link
2025-03-05 (ET)
2025-03-05
16:38:16
Mustang Bio regains compliance with Nasdaq requirement
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
08-29Yahoo Finance
Cascade Prodrug Inc. Names Industry Experts Manuel (Manny) Litchman and Andres Gutierrez to Its Board of Directors

  • New Board Appointments: Cascade Prodrug, Inc. has appointed Dr. Manuel Litchman and Dr. Andres Gutierrez to its Board of Directors, enhancing its leadership in oncology-focused biotechnology.

  • Dr. Litchman's Background: Dr. Litchman brings over 30 years of experience in biopharmaceuticals, having held leadership roles at Mustang Bio and Arvinas, with a strong focus on drug development and oncology.

  • Dr. Gutierrez's Expertise: Dr. Gutierrez is recognized for his extensive experience in clinical development and oncology, previously serving as Chief Medical Officer at several biotech companies and leading various successful drug trials.

  • Company Focus: Cascade is developing hypoxia activated therapies, with their lead candidate CPD100Li showing promise against multiple tumor types and entering IND-enabling studies targeting pancreatic cancer and other hypoxic tumors.

[object Object]
Preview
2.0
07-09Benzinga
Calidi Biotherapeutics Stock Jumps 39% After Hours — What's Going On

  • Stock Surge: Calidi Biotherapeutics Inc (CLDI) saw a significant after-hours stock surge of 39.47%, increasing its price from $0.24 to $0.34, driven by investor confidence in its innovative cancer treatment approaches.

  • Market Context: The rise in CLDI's stock coincides with broader movements in the healthcare sector, including notable gains from other biotech companies, indicating heightened investor interest in potential opportunities within the industry.

[object Object]
Preview
2.0
07-08TipRanks
3 Penny Stocks to Watch Now, 7/8/25

  • Penny Stocks to Watch: Mustang Bio, Sonnet BioTherapeutics, and SaverOne 2014 Ltd. are highlighted as top penny stocks on July 8, 2025, with significant Dollar Volumes and stock price increases, particularly Mustang Bio which received FDA Orphan Drug Designation for its cancer treatment candidate.

  • Market Insights: The TipRanks’ Penny Stock Screener tool is utilized to identify these stocks based on various parameters, including market performance metrics like Dollar Volume, which reflects the trading activity of these companies.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Mustang Bio Inc (MBIO) stock price today?

The current price of MBIO is 1.32 USD — it has increased 10.92 % in the last trading day.

arrow icon

What is Mustang Bio Inc (MBIO)'s business?

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for cancers and autoimmune diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. It is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. It has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.

arrow icon

What is the price predicton of MBIO Stock?

Wall Street analysts forecast MBIO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MBIO is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Mustang Bio Inc (MBIO)'s revenue for the last quarter?

Mustang Bio Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Mustang Bio Inc (MBIO)'s earnings per share (EPS) for the last quarter?

Mustang Bio Inc. EPS for the last quarter amounts to -0.07 USD, decreased -96.34 % YoY.

arrow icon

What changes have occurred in the market's expectations for Mustang Bio Inc (MBIO)'s fundamentals?

The market is revising No Change the revenue expectations for Mustang Bio, Inc. (MBIO) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -7.69%.
arrow icon

How many employees does Mustang Bio Inc (MBIO). have?

Mustang Bio Inc (MBIO) has 6 emplpoyees as of December 05 2025.

arrow icon

What is Mustang Bio Inc (MBIO) market cap?

Today MBIO has the market capitalization of 9.63M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free